Daclizumab Subcutaneous and Kisqali (200 MG Dose)
Determining the interaction of Daclizumab Subcutaneous and Kisqali (200 MG Dose) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using daclizumab together with ribociclib can cause serious side effects that may affect your liver. Call your doctor immediately if you experience a fever, chills, joint pain or swelling, excessive tiredness or weakness, unusual bleeding or bruising, skin rash or itching, loss of appetite, nausea, vomiting, or yellowing of the skin or the whites of your eyes. If your doctor prescribes these medications together, you may need a dose adjustment or special tests to safely take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration of daclizumab with other agents known to induce hepatotoxicity may increase the risk of liver injury. Serious drug-related hepatic injury, including liver failure and autoimmune hepatitis, has been reported across controlled and open-label studies in 1.7% of daclizumab-treated patients and may occur at any time during treatment and up to 5 months after treatment cessation. Fatal cases have occurred. In addition, cases of hepatic injury have occurred in patients taking daclizumab concomitantly with other hepatotoxic drugs; however, the contributory role of these other medicines has not been established.
MANAGEMENT: Caution is advised if daclizumab is used with other potentially hepatotoxic agents, including non-prescription products and herbal supplements. Patients treated with daclizumab should have serum transaminase levels and total bilirubin measured prior to initiation of treatment and monthly during treatment in accordance with the manufacturer's recommendations, and the dosing adjusted or interrupted as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Zinbryta (daclizumab)." AbbVie US LLC, North Chicago, IL.
Generic Name: daclizumab
Brand name: Zinbryta, Zenapax
Synonyms: Daclizumab
Generic Name: ribociclib
Brand name: Kisqali
Synonyms: Kisqali
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Daclizumab Subcutaneous-Kisqali (400 MG Dose)
- Daclizumab Subcutaneous-Kisqali (600 MG Dose)
- Daclizumab Subcutaneous-Kisqali Femara Co-Pack
- Daclizumab Subcutaneous-Kisqali Femara Co-Pack 200 mg-2.5 mg Dose
- Daclizumab Subcutaneous-Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
- Daclizumab Subcutaneous-Kisqali Femara Co-Pack 600 mg-2.5 mg Dose
- Kisqali (200 MG Dose)-Dacogen
- Kisqali (200 MG Dose)-Dacomitinib
- Kisqali (200 MG Dose)-Dactinomycin
- Kisqali (200 MG Dose)-Dactinomycin Injection
- Kisqali (200 MG Dose)-Dactinomycin Intravenous
- Kisqali (200 MG Dose)-Daklinza